Quick Answer
Kura Oncology, Inc. reported Revenue (ASC 606) of $67.48 million for fiscal year 2025.
Kura Oncology, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $67.48M | +25.2% |
| 2024 | $53.88M | — |
| 2023 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $20.75M | — | +35.7% |
| June 30, 2025 | $15.29M | — | +8.4% |
| March 31, 2025 | $14.11M | — | — |
- Kura Oncology, Inc. showed an increase of +25.2% in Revenue (ASC 606) compared to the prior fiscal year.
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: